Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records.
Regression discontinuity
Statins
Treatment effects
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
28
06
2022
accepted:
27
02
2023
medline:
11
4
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
Regression discontinuity design (RDD) is a quasi-experimental method intended for causal inference in observational settings. While RDD is gaining popularity in clinical studies, there are limited real-world studies examining the performance on estimating known trial casual effects. The goal of this paper is to estimate the effect of statins on myocardial infarction (MI) using RDD and compare with propensity score matching and Cox regression. For the RDD, we leveraged a 2008 UK guideline that recommends statins if a patient's 10-year cardiovascular disease (CVD) risk score > 20%. We used UK electronic health record data from the Health Improvement Network on 49,242 patients aged 65 + in 2008-2011 (baseline) without a history of CVD and no statin use in the two years prior to the CVD risk score assessment. Both the regression discontinuity (n = 19,432) and the propensity score matched populations (n = 24,814) demonstrated good balance of confounders. Using RDD, the adjusted point estimate for statins on MI was in the protective direction and similar to the statin effect observed in clinical trials, although the confidence interval included the null (HR = 0.8, 95% CI 0.4, 1.4). Conversely, the adjusted estimates using propensity score matching and Cox regression remained in the harmful direction: HR = 2.42 (95% CI 1.96, 2.99) and 2.51 (2.12, 2.97). RDD appeared superior to other methods in replicating the known protective effect of statins with MI, although precision was poor. Our findings suggest that, when used appropriately, RDD can expand the scope of clinical investigations aimed at causal inference by leveraging treatment rules from everyday clinical practice.
Identifiants
pubmed: 36935439
doi: 10.1007/s10654-023-00982-w
pii: 10.1007/s10654-023-00982-w
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-402Subventions
Organisme : NIA NIH HHS
ID : R56-AG061177
Pays : United States
Organisme : NIA NIH HHS
ID : R56-AG061177
Pays : United States
Informations de copyright
© 2023. Springer Nature B.V.
Références
Cholesterol Treatment Trialists C, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
Force UPST. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2022;328(8):746–53.
doi: 10.1001/jama.2022.13044
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (Lond Engl). 2002;360(9346):1623–30.
doi: 10.1016/S0140-6736(02)11600-X
Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177(7):955–65.
pubmed: 28531241
pmcid: 5543335
doi: 10.1001/jamainternmed.2017.1442
Venkataramani AS, Bor J, Jena AB. Regression discontinuity designs in healthcare research. BMJ. 2016;352: i1216.
pubmed: 26977086
pmcid: 6884311
doi: 10.1136/bmj.i1216
Wallace J, Jiang K, Goldsmith-Pinkham P, Song Z. Changes in racial and ethnic disparities in access to care and health among US adults at age 65 years. JAMA Intern Med. 2021;181(9):1207–15.
pubmed: 34309621
pmcid: 8314180
doi: 10.1001/jamainternmed.2021.3922
Fukuma S, Iizuka T, Ikenoue T, Tsugawa Y. Association of the national health guidance intervention for obesity and cardiovascular risks with health outcomes among Japanese men. JAMA Intern Med. 2020;180(12):1630–7.
pubmed: 33031512
pmcid: 7536624
doi: 10.1001/jamainternmed.2020.4334
Maciejewski ML, Basu A. Regression discontinuity design. JAMA. 2020;324(4):381–2.
pubmed: 32614409
doi: 10.1001/jama.2020.3822
Desai S, McWilliams JM. Consequences of the 340B drug pricing program. N Engl J Med. 2018;378(6):539–48.
pubmed: 29365282
pmcid: 6073067
doi: 10.1056/NEJMsa1706475
Hutcheon JA, Harper S, Liauw J, Skoll MA, Srour M, Strumpf EC. Antenatal corticosteroid administration and early school age child development: a regression discontinuity study in British Columbia, Canada. PLoS Med. 2020;17(12):e1003435.
pubmed: 33284805
pmcid: 7721186
doi: 10.1371/journal.pmed.1003435
Goulden R, Rowe BH, Abrahamowicz M, Strumpf E, Tamblyn R. Association of intravenous radiocontrast with kidney function: a regression discontinuity analysis. JAMA Intern Med. 2021;181(6):767–74.
pubmed: 33818606
pmcid: 8022267
doi: 10.1001/jamainternmed.2021.0916
Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ (Clin Res Ed). 2018;360: j5463.
doi: 10.1136/bmj.j5463
Chen S, Sudharsanan N, Huang F, Liu Y, Geldsetzer P, Bärnighausen T. Impact of community based screening for hypertension on blood pressure after two years: regression discontinuity analysis in a national cohort of older adults in China. BMJ. 2019;366:l4064.
Sudharsanan N, Chen S, Barnighausen T, Geldsetzer P. The effect of home-based hypertension screening on blood pressure change over time in South Africa. Health Aff (Millwood). 2020;39(1):124–132.
Cattaneo MD, Titiunik R. Regression discontinuity designs. Ann. Rev Econ. 2022;14 (forthcoming).
Hahn J, Todd P, Van der Klaauw W. Identification and estimation of treatment effects with a regression-discontinuity design. Econometrica. 2001;69(1):201–209
Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit. 2010;48(2):281–355.
doi: 10.1257/jel.48.2.281
Thistlethwaite DL, Campbell DT. Regression-discontinuity analysis: An alternative to the ex post facto experiment. J Educ Psychol. 1960;51:309–317.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34–9.
pubmed: 17916661
doi: 10.1136/hrt.2007.134890
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
doi: 10.1093/biomet/70.1.41
Smith LM, Lévesque LE, Kaufman JS, Strumpf EC. Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme. Int J Epidemiol. 2016;46(3):939–49.
pmcid: 5837477
Cattaneo MD, Idrobo N, Titiunik R. A practical introduction to regression discontinuity designs: foundations. Cambridge: Cambridge University Press; 2019.
doi: 10.1017/9781108684606
Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5.
pubmed: 22828580
Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236–40.
pubmed: 23248196
pmcid: 3631834
doi: 10.2337/dc12-1756
Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109.
pubmed: 19006546
pmcid: 2668090
doi: 10.1111/j.1365-2125.2008.03308.x
Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393–401.
pubmed: 17066486
doi: 10.1002/pds.1335
Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76–83.
pubmed: 19065600
doi: 10.1002/pds.1688
Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf. 2010;19(6):579–85.
pubmed: 20131328
doi: 10.1002/pds.1919
Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–7.
pubmed: 15606990
Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293–8.
pubmed: 1985385
doi: 10.1016/0002-8703(91)90861-B
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136.
pubmed: 17615182
pmcid: 1925200
doi: 10.1136/bmj.39261.471806.55
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.
pubmed: 18573856
pmcid: 2440904
doi: 10.1136/bmj.39609.449676.25
Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419–25.
pubmed: 9643612
pmcid: 1873548
doi: 10.1046/j.1365-2125.1998.00701.x
Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18(8):704–7.
pubmed: 19455565
doi: 10.1002/pds.1770
Chisholm J. The Read clinical classification. BMJ. 1990;300(6732):1092.
pubmed: 2344534
pmcid: 1662793
doi: 10.1136/bmj.300.6732.1092
Calonico S, Cattaneo MD, Titiunik R. Robust nonparametric confidence intervals for regression-discontinuity designs. Econometrica. 2014;82(6):2295–326.
doi: 10.3982/ECTA11757
Calonico S, Cattaneo MD, Titiunik R. Optimal data-driven regression discontinuity plots. J Am Stat Assoc. 2015;110(512):1753–69.
doi: 10.1080/01621459.2015.1017578
Imbens G, Kalyanaraman K. Optimal bandwidth choice for the regression discontinuity estimator. Rev Econ Stud. 2011;79(3):933–59.
doi: 10.1093/restud/rdr043
Calonico S, Cattaneo MD, Farrell MH, Titiunik R. Regression discontinuity designs using covariates. Rev Econ Stat. 2019;101(3):442–51.
doi: 10.1162/rest_a_00760
Calonico S, Cattaneo MD, Farrell MH, Titiunik R. rdrobust: software for regression-discontinuity designs. Stata J. 2017;17(2):372–404.
doi: 10.1177/1536867X1701700208
Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
Geneletti S, O’Keeffe AG, Sharples LD, Richardson S, Baio G. Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data. Stat Med. 2015;34(15):2334–52.
pubmed: 25809691
pmcid: 4856212
doi: 10.1002/sim.6486
O’Keeffe AG, Geneletti S, Baio G, Sharples LD, Nazareth I, Petersen I. Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. BMJ (Clinical research ed). 2014;349:g5293.
pubmed: 25199521
Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.
pubmed: 22658145
doi: 10.1016/j.jacl.2012.03.003
Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014;129(7):754–63.
pubmed: 24326988
doi: 10.1161/CIRCULATIONAHA.113.002658
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.
pubmed: 12132976
doi: 10.1001/jama.288.4.462
Adams J, Ryan V, White M. How accurate are Townsend Deprivation Scores as predictors of self-reported health? A comparison with individual level data. J Public Health (Oxf). 2005;27(1):101–6.
pubmed: 15564276
doi: 10.1093/pubmed/fdh193
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–31.
pubmed: 27040132
doi: 10.1056/NEJMoa1600176
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.
pubmed: 20167359
doi: 10.1016/S0140-6736(09)61965-6
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
pubmed: 18997196
doi: 10.1056/NEJMoa0807646
Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.